Table 1 Patient demographic and baseline lesion data with GA enlargement characteristics
No. of eyes (n) | 10 |
No. of patients (n) | 6 |
Gender (m/f) | 0/6 |
Mean age (y) | 77 ± 2 (range: 75 to 79) |
Mean follow-up (years) | 5.06 ± 3.01 (2.01–9.68) |
before CNV diagnosis | 1.42 ± 0.48 (0.77–1.80) |
after CNV diagnosis | 3.64 ± 2.73 (1.15–7.88) |
Mean BCVA (logMAR) | |
Study eye (n = 6) | |
baseline | 0.84 ± 0.40 (0.30–1.30) |
at CNV diagnosis | 0.94 ± 0.44 (0.30–1.40) |
end of follow-up | 1.01 ± 0.57 (0.40–1.92) |
Partner eye (n = 4) | |
baseline | 1.09 ± 0.56 (0.50–2.00) |
end of follow-up | 1.24 ± 0.48 (0.50–2.00) |
Drusen | |
Soft | 5/10 (50%) |
SDD | 10/10 (100%) |
Choroidal thickness | |
Study eye | |
baseline (μm) | 152 ± 51 (71–224) |
last follow-up (μm) | 101 ± 44 (39–165) |
Partner eye | |
baseline (μm) | 130 ± 63 (46–222) |
last follow-up (μm) | 127 ± 99 (23–290) |
Geographic atrophy | |
Study eye (n = 6) | |
GA lesions baseline (n) | 2 ± 1 (1–4) |
Foveal involvement | 4/6 (66.7%) |
Phenotype | |
Banded | 3/6 (50%) |
Diffuse | 2/6 (33.3%) |
Diffuse Trickling | 1/6 (16.7%) |
GA baseline (mm2) | 2.11 ± 1.48 (0.79–4.35) |
GA CNV diagnosis (mm2) | 4.55 ± 2.98 (2.31–10.51) |
GA last follow-up (mm2) | 8.58 ± 3.50 (4.37–14.07) |